Patents by Inventor Gary M. Fox
Gary M. Fox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932802Abstract: Various shaped abrasive particles are disclosed. Each shaped abrasive particle includes a body having at least one major surface and a side surface extending from the major surface.Type: GrantFiled: December 2, 2022Date of Patent: March 19, 2024Assignee: SAINT-GOBAIN CERAMICS & PLASTICS, INC.Inventors: Todd M. Cotter, Francois Wagner, Rene G. Demers, Richard J. Klok, Alexandra Marazano, Adam D. Lior, James A. Salvatore, Sujatha K. Iyengar, David F Louapre, Sidath S. Wijesooriya, Ronald Christopher Motta, Gary A. Guertin, Michael D. Kavanaugh, Doruk O. Yener, Jennifer H. Czerepinski, Jun Jia, Frederic Josseaux, Ralph Bauer, Frank J. Csillag, Yang Zhong, James P. Stewart, Mark P. Dombrowski, Sandhya Jayaraman Rukmani, Amandine Martin, Stephen E. Fox, Nilanjan Sarangi, Dean S. Matsumoto
-
Publication number: 20090004237Abstract: The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides.Type: ApplicationFiled: June 27, 2008Publication date: January 1, 2009Applicant: AMGEN, INC.Inventors: Gary M. Fox, John K. Sullivan, Paige Holst, Steven Kiyoshi Yoshinaga
-
Patent number: 7414122Abstract: The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides.Type: GrantFiled: November 29, 2004Date of Patent: August 19, 2008Assignee: Amgen Inc.Inventors: Gary M. Fox, John K Sullivan, Paige Holst, Steven Kiyoshi Yoshinaga
-
Patent number: 7138251Abstract: The present invention relates to glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of receptors for GDNF. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmembrane signaling. GDNFR mRNA is widely distributed in both nervous system and non-neural tissues, consistent with the similar distribution found for GDNF.Type: GrantFiled: May 30, 1997Date of Patent: November 21, 2006Assignee: Amgen Inc.Inventors: Gary M. Fox, Shuqian Jing, Duanzhi Wen
-
Patent number: 6992175Abstract: Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.Type: GrantFiled: August 23, 1999Date of Patent: January 31, 2006Assignee: Amgen Inc.Inventors: Gary M. Fox, Andrew A. Welcher, Shuqian Jing
-
Publication number: 20040235714Abstract: The present invention relates to glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of receptors for GDNF. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmembrane signaling. GDNFR mRNA is widely distributed in both nervous system and non-neural tissues, consistent with the similar distribution found for GDNF.Type: ApplicationFiled: June 18, 2004Publication date: November 25, 2004Applicant: Amgen Inc.Inventors: Gary M. Fox, Shuqian Jing, Duanzhi Wen
-
Publication number: 20030175876Abstract: The present invention relates to glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of a high affinity receptor for GDNF. This molecule has been named GDNF receptor (GDNFR) since it is the first known component of a receptor system. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmembrane signaling.Type: ApplicationFiled: May 24, 2002Publication date: September 18, 2003Applicant: Amgen Inc.Inventors: Gary M. Fox, Shuqian Jing, Duanzhi Wen
-
Publication number: 20030077246Abstract: The present invention provides novel TNFr/OPG-like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies, and methods for producing TNFr/OPG-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases with TNFr/OPG-like polypeptides.Type: ApplicationFiled: May 15, 2002Publication date: April 24, 2003Inventors: Andrew A. Welcher, Gary M. Fox, Michael J. Boedigheimer, Junyan Shu, Shuqian Jing, Brian D. Bennett, Roland Luethy
-
Patent number: 6479250Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: July 7, 2000Date of Patent: November 12, 2002Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
-
Publication number: 20020165347Abstract: The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides.Type: ApplicationFiled: June 29, 2001Publication date: November 7, 2002Applicant: Amgen, Inc.Inventors: Gary M. Fox, John K. Sullivan, Mei Fang
-
Patent number: 6455277Abstract: The present invention relates to glial cell line-derived neurotophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of a high affinity receptor for GDNF. This molecule has been named GDNF receptor (GDNFR) since it is the first known component of a receptor system. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmembrane signaling.Type: GrantFiled: April 14, 1997Date of Patent: September 24, 2002Assignee: Amgen Inc.Inventors: Gary M. Fox, Shuqian Jing, Duanzhi Wen
-
Publication number: 20020107363Abstract: The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides.Type: ApplicationFiled: September 19, 2001Publication date: August 8, 2002Applicant: Amgen, Inc.Inventors: Gary M. Fox, John K. Sullivan, Paige Holst, Steven Kiyoshi Yoshinaga
-
Patent number: 6169167Abstract: Polypeptides which bind to one or more EPH-like receptors, particularly the HEK4 receptor, are described. The polypeptides are designated HEK4 binding proteins. Nucleic acids encoding HEK4 binding proteins, and expression vectors, host cells and processes for the production of the polypeptides are also described. The polypeptides are useful for modulating the growth and/or differentiation of a variety of tissues, including those from liver, kidney, lung, skin, digestive tract and nervous system and may be used to regenerate damaged or depleted tissue and to treat cancer or nervous system disorders.Type: GrantFiled: March 25, 1998Date of Patent: January 2, 2001Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Gary M. Fox
-
Patent number: 6087167Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: October 28, 1997Date of Patent: July 11, 2000Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
-
Patent number: 6063903Abstract: Polypeptides which bind to one or more EPH-like receptors, particularly the HEK4 receptor, are described. The polypeptides are designated HEK4 binding proteins. Nucleic acids encoding HEK4 binding proteins, and expression vectors, host cells and processes for the production of the polypeptides are also described. The polypeptides are useful for modulating the growth and/or differentiation of a variety of tissues, including those from liver, kidney, lung, skin, digestive tract and nervous system and may be used to regenerate damaged or depleted tissue and to treat cancer or nervous system disorders.Type: GrantFiled: March 25, 1998Date of Patent: May 16, 2000Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Gary M. Fox
-
Patent number: 6057124Abstract: Polypeptides which bind to one or more EPH-like receptors, particularly the HEK4 receptor, are described. The polypeptides are designated HEK4 binding proteins. Nucleic acids encoding HEK4 binding proteins, and expression vectors, host cells and processes for the production of the polypeptides are also described. The polypeptides are useful for modulating the growth and/or differentiation of a variety of tissues, including those from liver, kidney, lung, skin, digestive tract and nervous system and may be used to regenerate damaged or depleted tissue and to treat cancer or nervous system disorders.Type: GrantFiled: January 27, 1995Date of Patent: May 2, 2000Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Gary M. Fox
-
Patent number: 5981246Abstract: Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.Type: GrantFiled: August 21, 1996Date of Patent: November 9, 1999Assignee: Amgen Inc.Inventors: Gary M. Fox, Andrew A. Welcher, Shuqian Jing
-
Patent number: 5981245Abstract: Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.Type: GrantFiled: May 24, 1995Date of Patent: November 9, 1999Assignee: Amgen Inc.Inventors: Gary M. Fox, Andrew A. Welcher, Shuqian Jing
-
Patent number: 5824303Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: May 19, 1995Date of Patent: October 20, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
-
Patent number: 5716934Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: May 30, 1995Date of Patent: February 10, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Vann P. Parker, Gary M. Fox, Andrew A. Welcher